Premium
Fbxo6 confers drug‐sensitization to cisplatin via inhibiting the activation of Chk1 in non‐small cell lung cancer
Author(s) -
Cai Lin,
Li Jingduo,
Zhao Jing,
Guo Yingxue,
Xie Menghua,
Zhang Xiupeng,
Wang Liang,
Tian Hua,
Li Ailin,
Li Qingchang,
Miao Yuan
Publication year - 2019
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1002/1873-3468.13461
Subject(s) - sensitization , cisplatin , lung cancer , drug , chemistry , pharmacology , cancer research , medicine , oncology , immunology , chemotherapy
Fbxo6 (also called FBG 2) is a critical component of the evolutionarily conserved ubiquitin–protein ligase complex SCF (Skp1/Cdc53‐Cullin1/F‐box). Previous studies have demonstrated that Fbxo6 facilitates the growth and proliferation but inhibits the apoptosis and invasion of gastric cancer cells. However, the role of Fbxo6 in non‐small cell lung cancer ( NSCLC ) is still not clear. Our results revealed that Fbxo6 expression is correlated with early TNM stage and favorable overall survival of NSCLC patients. Further in vitro experiments showed that Fbxo6 inhibits proliferation, facilitates apoptosis and promotes the sensitivity of cisplatin via decreased expression and phosphorylation of Chk1. Thus, Fbxo6 may be a useful prognosis marker and therapeutic target to overcome the chemoresistance of cisplatin‐based chemotherapy agents in NSCLC patients.